Has Peter Miller, MD received payments from drug or device companies?

Yes. Drug and device makers reported $62,415 in general payments to Peter Miller, MD across 34 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Peter Miller, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Peter Miller, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Peter Miller, MD

Medical Oncology · Boston, MANPI 1720426281

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $52,939 of the $62,415 with a category attached, or 84.8%. Foundation Medicine, Inc. accounts for 96.3% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $26,875 and has fallen 99.2% since, to $209 in 2024.

$62,415in general payments, 2019–2025

Across 34 payments — averaging $1835.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Foundation Medicine, Inc.$60K
F. Hoffmann-la Roche AG$2K
Daiichi Sankyo Inc.$192
AstraZeneca$17

What the payments were for

Consulting fees$52,93985%
Speaking & faculty fees$7,16611%
Travel & lodging$1,6973%
Food & beverage$6131%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Foundation Medicine, Inc.	29	$60,105
F. Hoffmann-la Roche AG	3	$2,101
Daiichi Sankyo Inc.	1	$192
AstraZeneca	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,415 in reported general payments places this provider in the 80th percentile of 308 medical oncology providers in Massachusetts.

See all medical oncology providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$14,334

Medicare patients

Services billed

165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Boston

George DemetriBoston$1.6M
Keith FlahertyBoston$932K
Alicia MorgansBoston$690K
Pasi Antero JanneBoston$458K
Robert HaddadBoston$451K
Irene GhobrialBoston$431K
Joaquin Bellmunt MolinsBoston$415K
Jeremy AbramsonBoston$334K
Justin GainorBoston$324K
Narjust FlorezBoston$324K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →